The Birmingham Experimental Cancer Medicine Centre (ECMC), jointly funded by Cancer Research UK and the National Institute for Health Research, is led by Professor Gary Middleton and has an international reputation for innovation in personalised medicine, with the development of novel, stratified studies driven in partnership with the CRUK Clinical Trials Unit.

Research is developed at UHB, with University of Birmingham providing academic leadership. Strengths of the ECMC include the National Lung Matrix Trial, the development of innovative immunotherapeutic strategies and experimental haematology studies. Most recently, the Bladder Cancer Centre has been launched, led by Birmingham’s Dr Rik Bryan working in collaboration with the universities of Oxford, Cardiff and Manchester.